Nordea Investment Management AB Has $1.71 Million Stock Holdings in Natera, Inc. $NTRA

Nordea Investment Management AB raised its stake in Natera, Inc. (NASDAQ:NTRA) by 7.3% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 10,152 shares of the medical research company’s stock after purchasing an additional 687 shares during the period. Nordea Investment Management AB’s holdings in Natera were worth $1,711,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of NTRA. WCM Investment Management LLC grew its position in shares of Natera by 8.2% in the second quarter. WCM Investment Management LLC now owns 6,465 shares of the medical research company’s stock valued at $1,086,000 after purchasing an additional 490 shares during the last quarter. Ritholtz Wealth Management acquired a new stake in shares of Natera during the second quarter worth $296,000. Harbour Investments Inc. increased its position in Natera by 120.9% during the second quarter. Harbour Investments Inc. now owns 2,171 shares of the medical research company’s stock worth $367,000 after acquiring an additional 1,188 shares during the period. Bayforest Capital Ltd raised its stake in Natera by 15.7% in the 2nd quarter. Bayforest Capital Ltd now owns 3,057 shares of the medical research company’s stock worth $516,000 after purchasing an additional 414 shares in the last quarter. Finally, TD Asset Management Inc boosted its holdings in Natera by 12.8% in the 2nd quarter. TD Asset Management Inc now owns 117,948 shares of the medical research company’s stock valued at $19,926,000 after purchasing an additional 13,402 shares during the period. Institutional investors and hedge funds own 99.90% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently commented on NTRA. Canaccord Genuity Group reaffirmed a “buy” rating and set a $200.00 target price on shares of Natera in a report on Tuesday, October 14th. Zacks Research downgraded Natera from a “hold” rating to a “strong sell” rating in a research note on Monday. Weiss Ratings restated a “sell (d-)” rating on shares of Natera in a research report on Wednesday, October 8th. Barclays reiterated an “overweight” rating and set a $210.00 price target (up previously from $190.00) on shares of Natera in a research report on Friday, August 8th. Finally, Cowen restated a “buy” rating on shares of Natera in a research report on Friday, August 8th. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $196.81.

Insider Transactions at Natera

In other news, CFO Michael Burkes Brophy sold 602 shares of the business’s stock in a transaction dated Tuesday, October 21st. The stock was sold at an average price of $187.95, for a total transaction of $113,145.90. Following the sale, the chief financial officer directly owned 70,109 shares in the company, valued at approximately $13,176,986.55. The trade was a 0.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider John Fesko sold 339 shares of the company’s stock in a transaction that occurred on Tuesday, October 21st. The shares were sold at an average price of $187.95, for a total value of $63,715.05. Following the completion of the transaction, the insider directly owned 152,408 shares of the company’s stock, valued at $28,645,083.60. This represents a 0.22% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 70,276 shares of company stock worth $10,794,948. Insiders own 5.63% of the company’s stock.

Natera Trading Up 0.6%

Shares of Natera stock opened at $188.02 on Thursday. The firm’s 50 day moving average is $169.97 and its 200 day moving average is $159.37. The firm has a market capitalization of $25.81 billion, a PE ratio of -98.44 and a beta of 1.74. Natera, Inc. has a 1 year low of $117.27 and a 1 year high of $196.63.

Natera (NASDAQ:NTRA) last issued its earnings results on Thursday, August 7th. The medical research company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.14). The company had revenue of $546.60 million during the quarter, compared to analyst estimates of $476.84 million. Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. The business’s quarterly revenue was up 32.2% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.30) EPS. Natera has set its FY 2025 guidance at EPS. As a group, research analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current year.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.